Subtype
Nasopharyngeal Neoplasm
CI-CAN-00003401Explore in graph →
Non-malignant267 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003401Explore in graph →
Clinical trials
825 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06235203 | Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC | recruiting | Phase 3 | 154 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000643 | Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 386 | Man HuOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06749899 |
| QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma. |
| recruiting |
| Phase 3 |
| 580 |
| Sun Yat-Sen University Cancer CenterOTHER |
| 1 |
| May 22, 2025 |
| clinicaltrials |
| NCT06912698 | Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma | recruiting | Phase 3 | 342 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04974398 | A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 296 | AkesoINDUSTRY | 5 | Apr 13, 2025 | clinicaltrials |
| NCT06752239 | Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC(PROTECT-NPC) | recruiting | Phase 3 | 474 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06900218 | PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 664 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05304468 | Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain | active not recruiting | Phase 3 | 452 | Sun Yat-sen UniversityOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06095154 | CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05587374 | Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)(GEMSTONE) | active not recruiting | Phase 3 | 490 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06775756 | Reducing Dose and Irradiated Volume in Cervical Prophylactic Irradiation for Nasopharyngeal Cancer | not yet recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 15, 2025 | clinicaltrials |
| NCT03840421 | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 468 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05869227 | Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 166 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06669611 | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 242 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT02460887 | The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | active not recruiting | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06675214 | Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy. | recruiting | Phase 3 | 586 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06664983 | TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06516133 | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma(OART) | recruiting | Phase 3 | 494 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06383780 | Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. | recruiting | Phase 3 | 90 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | recruiting | Phase 3 | 164 | XIANG YANQUNOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06241599 | A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | recruiting | Phase 2 / Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06092957 | Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy | recruiting | Phase 3 | 504 | Sun Yat-sen UniversityOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06095167 | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC | not yet recruiting | Phase 3 | 476 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06026878 | GNT Induction Treatment in Locally Advanced NPC | recruiting | Phase 3 | 228 | Air Force Military Medical University, ChinaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03919552 | Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 482 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05877872 | Reduced-target Resection After Induction Chemotherapy in Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 424 | Sun Yat-sen UniversityOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT03306121 | TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 322 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05860868 | Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 474 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | recruiting | Phase 3 | 244 | Sun Yat-sen UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05527470 | Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 440 | Wei JiangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05780294 | A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC | not yet recruiting | Phase 3 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT05772208 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | recruiting | Phase 3 | 459 | Fudan UniversityOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05717764 | Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment | not yet recruiting | Phase 3 | 500 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.INDUSTRY | 0 | Feb 8, 2023 | clinicaltrials |
| NCT05674305 | Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy | recruiting | Phase 3 | 366 | Fudan UniversityOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05433597 | A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC | not yet recruiting | Phase 2 / Phase 3 | 172 | Sun Yat-sen UniversityOTHER | 0 | Jun 27, 2022 | clinicaltrials |
| NCT04437329 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 352 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05062005 | ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 447 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04376866 | Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04890522 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | not yet recruiting | Phase 2 / Phase 3 | 622 | Sun Yat-sen UniversityOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04778956 | Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 218 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04215510 | Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT | not yet recruiting | Phase 3 | 286 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04448522 | Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma | recruiting | Phase 3 | 508 | Sun Yat-sen UniversityOTHER | 2 | Sep 28, 2020 | clinicaltrials |
| NCT04453813 | Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 226 | Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04453826 | Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 388 | Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04136886 | Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma(IMRT) | recruiting | Phase 3 | 346 | Sun Yat-sen UniversityOTHER | 1 | Oct 23, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jun 3, 2025source: clinicaltrials